Neuronetics, Inc. (NASDAQ:STIM) Short Interest Down 37.3% in November

Neuronetics, Inc. (NASDAQ:STIM) saw a significant decrease in short interest in November. As of November 30th, there was short interest totalling 607,300 shares, a decrease of 37.3% from the November 15th total of 969,100 shares. Based on an average trading volume of 452,500 shares, the short-interest ratio is presently 1.3 days.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in STIM. Assenagon Asset Management S.A. boosted its holdings in Neuronetics by 63.0% during the second quarter. Assenagon Asset Management S.A. now owns 135,746 shares of the company’s stock worth $244,000 after purchasing an additional 52,450 shares during the last quarter. Legato Capital Management LLC acquired a new position in Neuronetics during the second quarter worth $44,000. Acadian Asset Management LLC boosted its holdings in Neuronetics by 23.7% during the second quarter. Acadian Asset Management LLC now owns 326,975 shares of the company’s stock worth $587,000 after purchasing an additional 62,628 shares during the last quarter. Dorsey & Whitney Trust CO LLC boosted its holdings in Neuronetics by 97.1% during the second quarter. Dorsey & Whitney Trust CO LLC now owns 95,880 shares of the company’s stock worth $173,000 after purchasing an additional 47,228 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in Neuronetics by 124.5% during the second quarter. Renaissance Technologies LLC now owns 322,200 shares of the company’s stock worth $580,000 after purchasing an additional 178,700 shares during the last quarter. Institutional investors and hedge funds own 53.59% of the company’s stock.

Neuronetics Stock Performance

Shares of STIM opened at $1.12 on Friday. Neuronetics has a 12 month low of $0.52 and a 12 month high of $5.07. The firm has a fifty day simple moving average of $0.98 and a 200 day simple moving average of $1.28. The stock has a market capitalization of $33.99 million, a price-to-earnings ratio of -0.91 and a beta of 2.25. The company has a current ratio of 3.16, a quick ratio of 2.87 and a debt-to-equity ratio of 4.90.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.